Metsera, Inc. — Investor Relations & Filings

Metsera, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and related metabolic diseases. The company's portfolio includes both injectable and oral therapeutic candidates based on nutrient-stimulated hormone (NuSH) analog peptides. Leveraging a proprietary peptide engineering platform, Metsera aims to create potent, ultra-long-acting therapies with improved durability, bioavailability, and manufacturability. The company's approach is designed to deliver scalable treatments, including oral options with injectable-like performance, to enhance effectiveness, tolerability, and long-term patient adherence.